New hope for tough leukemia: drug combo targets resistant cancer
Disease control
Not yet recruiting
This study tests a drug called olutasidenib in 25 adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated) that has returned or not responded to treatment, including the drug venetoclax. Participants take olutasidenib pills twice daily for 28-day cycles. If th…
Phase: PHASE2 • Sponsor: Timothy Pardee • Aim: Disease control
Last updated May 18, 2026 12:01 UTC